GlassScriptPhysician profile
Marcus Anthony Urey
NPI 1972820058
$340,944.54
in general payments reported to CMS, 2019-2025
21 companies · $76K in 2025
The $76K reported for 2025 was more than what 96% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $19K · 2021: $12K · 2022: $30K · 2023: $21K · 2024: $110K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Consulting Fee: $44K · Travel and Lodging: $27K · Food and Beverage: $5,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,315.38 |
| Consulting Fee | $43,952.50 |
| Travel and Lodging | $26,695.59 |
| Food and Beverage | $5,413.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $132,390.14 | 2019-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $83,526.18 | 2022-2025 | Wainua |
| Bridgebio Pharma, INC. | $44,004.59 | 2025 | Attruby |
| Pfizer INC. | $41,510.34 | 2019-2024 | |
| Akcea Therapeutics, INC. | $18,726.17 | 2019-2020 | |
| Edwards Lifesciences Corporation | $13,202.78 | 2022-2025 | |
| Abiomed | $3,923.13 | 2021-2025 | Impella |
| Abbott Laboratories | $2,476.55 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, 2nd Gen Centrimag Primary Console |
| Medtronic Vascular, INC. | $345.31 | 2019 | |
| Boston Scientific Corporation | $299.05 | 2019-2022 | |
| Paragonix Technologies, INC. | $162.73 | 2024 | Sherpapak, Liverguard, Pancreaspak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.96 | 2021 | |
| Cvrx, INC. | $100.65 | 2023 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.59 | 2024 | Lifevest |
| Endotronix, INC. | $49.75 | 2023 | Cordella Pulomonary Artery Pressure Sensor |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $19.07 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.55 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$209,803.76 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Urey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.